244 related articles for article (PubMed ID: 19006102)
1. Metabolite profiling of fecal water extracts from human colorectal cancer.
Monleón D; Morales JM; Barrasa A; López JA; Vázquez C; Celda B
NMR Biomed; 2009 Apr; 22(3):342-8. PubMed ID: 19006102
[TBL] [Abstract][Full Text] [Related]
2. Detecting colorectal cancer by 1H magnetic resonance spectroscopy of fecal extracts.
Bezabeh T; Somorjai R; Dolenko B; Bryskina N; Levin B; Bernstein CN; Jeyarajah E; Steinhart AH; Rubin DT; Smith IC
NMR Biomed; 2009 Jul; 22(6):593-600. PubMed ID: 19259992
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of calgranulin B in stools from the patients with colorectal cancer.
Yoo BC; Shin YK; Lim SB; Hong SH; Jeong SY; Park JG
Dis Colon Rectum; 2008 Nov; 51(11):1703-9. PubMed ID: 18584251
[TBL] [Abstract][Full Text] [Related]
4. (1)H NMR metabolite profiling of feces as a tool to assess the impact of nutrition on the human microbiome.
Jacobs DM; Deltimple N; van Velzen E; van Dorsten FA; Bingham M; Vaughan EE; van Duynhoven J
NMR Biomed; 2008 Jul; 21(6):615-26. PubMed ID: 18085514
[TBL] [Abstract][Full Text] [Related]
5. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
[TBL] [Abstract][Full Text] [Related]
6. MR metabolomics of fecal extracts: applications in the study of bowel diseases.
Bezabeh T; Somorjai RL; Smith IC
Magn Reson Chem; 2009 Dec; 47 Suppl 1():S54-61. PubMed ID: 19842159
[TBL] [Abstract][Full Text] [Related]
7. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS).
Chan EC; Koh PK; Mal M; Cheah PY; Eu KW; Backshall A; Cavill R; Nicholson JK; Keun HC
J Proteome Res; 2009 Jan; 8(1):352-61. PubMed ID: 19063642
[TBL] [Abstract][Full Text] [Related]
8. [Fecal oncomarkers in the diagnostics of colorectal cancer].
Mikhaĭlova EI; Pimanov SI; Voropaev EV
Klin Med (Mosk); 2007; 85(12):62-7. PubMed ID: 18318171
[TBL] [Abstract][Full Text] [Related]
9. [Study on specific metabonomic profiling of serum from colorectal cancer patients by gas chromatography-mass spectrometry].
Ma YL; Liu WJ; Peng JY; Zhang P; Chen HQ; Qin HL
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jul; 12(4):386-90. PubMed ID: 19598026
[TBL] [Abstract][Full Text] [Related]
10. Fecal lysozyme: an unreliable marker for colorectal cancer.
Dubrow R; Kim CS; Eldred AK
Am J Gastroenterol; 1992 May; 87(5):617-21. PubMed ID: 1595650
[TBL] [Abstract][Full Text] [Related]
11. Effects on cell proliferation, activator protein-1 and genotoxicity by fecal water from patients with colorectal adenomas.
Nordling MM; Glinghammar B; Karlsson PC; de Kok TM; Rafter JJ
Scand J Gastroenterol; 2003 May; 38(5):549-55. PubMed ID: 12795469
[TBL] [Abstract][Full Text] [Related]
12. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
Inadomi JM
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S198-204. PubMed ID: 19120898
[TBL] [Abstract][Full Text] [Related]
13. [Proton nuclear magnetic resonance spectroscopy recognition of metabolic patterns in fecal extracts for early diagnosis of colorectal cancer].
Lin Y; Wang ZN; Ma CC; Liu CK; Yang JR; Shen ZW; Wu RH
Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Sep; 50(9):788-793. PubMed ID: 27655598
[No Abstract] [Full Text] [Related]
14. Fecal protein markers of colorectal cancer.
Dubrow R; Yannielli L
Am J Gastroenterol; 1992 Jul; 87(7):854-8. PubMed ID: 1615938
[TBL] [Abstract][Full Text] [Related]
15. NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer.
Lin Y; Ma C; Liu C; Wang Z; Yang J; Liu X; Shen Z; Wu R
Oncotarget; 2016 May; 7(20):29454-64. PubMed ID: 27107423
[TBL] [Abstract][Full Text] [Related]
16. Nucleic acids from intact epithelial cells as a target for stool-based molecular diagnosis of colorectal cancer.
Spethmann S; Fischer C; Wagener C; Streichert T; Tschentscher P
Int J Mol Med; 2004 Mar; 13(3):451-4. PubMed ID: 14767578
[TBL] [Abstract][Full Text] [Related]
17. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
[TBL] [Abstract][Full Text] [Related]
18. Kinetic analysis of bile acids in the feces of colorectal cancer patients by gas chromatography-mass spectrometry (GC-MS).
Tadano T; Kanoh M; Kondoh H; Matsumoto M; Mimura K; Kanoh Y; Sakamoto K; Kamano T
Rinsho Byori; 2007 May; 55(5):417-27. PubMed ID: 17593686
[TBL] [Abstract][Full Text] [Related]
19. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening.
Takai T; Kanaoka S; Yoshida K; Hamaya Y; Ikuma M; Miura N; Sugimura H; Kajimura M; Hishida A
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1888-93. PubMed ID: 19505922
[TBL] [Abstract][Full Text] [Related]
20.
Lin Y; Ma C; Bezabeh T; Wang Z; Liang J; Huang Y; Zhao J; Liu X; Ye W; Tang W; Ouyang T; Wu R
Int J Cancer; 2019 Sep; 145(6):1679-1689. PubMed ID: 30720869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
